



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

HFA-305

Food and Drug Administration
Rockville MD 20857

3014 '02 JUL 10 09:34

Shotwell & Carr, Inc.
Attention: Paul W. Carr
3535 Firewheel Dr., Suite A
Flower Mound, TX 75028-2628

JUL - 3 2002

Docket No. 01P-0526/CP1

Dear Mr. Carr:

This is in response to your petition filed on November 21, 2001, requesting permission to file an Abbreviated New Drug Application (ANDA) for the following drug product: Carisoprodol Tablets USP, 200 mg. The listed drug product to which you refer in your petition is Soma® (Carisoprodol) Tablets USP, 350 mg, NDA 11-792, held by Wallace Laboratories.

This petition was reviewed pursuant to Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (Act). Under Section 505(j)(2)(C)(i) of the Act such a petition will be approved unless the Food and Drug Administration (FDA) finds that investigations must be conducted to show the safety and effectiveness of the strength of the proposed drug product that differs from the strength of the listed drug product.

Your request involves a change in strength from that of the listed drug product (i.e. from 350 mg to 200 mg). The change that you request is the type of change that is authorized under Section 505(j)(2)(C) of the Act.

The FDA has determined that your proposed change in strength for carisoprodol raises questions of safety and effectiveness, and has concluded that clinical trials are required for this specific drug product. There is no information before the FDA that would indicate that a dose of 200 mg of carisoprodol would be effective for the labeled indications of the reference listed drug. Therefore, FDA is denying the petition under Section 505(j)(2)(C)(i) because investigations are necessary to show the safety and effectiveness of the proposed drug product.

If you disagree with our determination concerning the acceptability of your petition as originally submitted, you may seek a reconsideration of the denial following the procedures set forth in 21 CFR 10.33. Requests for reconsideration must be based solely on the information contained in your original petition and must be submitted in accordance with 21 CFR Section 10.20, in the format outlined in Section 10.33 and no later than 30 days after the date of the decision involved. Petitions for reconsideration should be filed with the Dockets Management Branch at the address listed below. If there is additional information, not included as part of your original submission that you would like the FDA to consider, you should submit a new petition including all the necessary information to the Dockets Management Branch.

01P-0526

PDN1

01P-0526/CP1

A copy of this letter denying your petition will be placed on public display in the Dockets Management Branch, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD 20852.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Gary Buehler". The signature is fluid and cursive, with a long horizontal stroke extending to the right.

Gary J. Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research